TR199802441A3 - Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip. - Google Patents

Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.

Info

Publication number
TR199802441A3
TR199802441A3 TR1998/02441A TR9802441A TR199802441A3 TR 199802441 A3 TR199802441 A3 TR 199802441A3 TR 1998/02441 A TR1998/02441 A TR 1998/02441A TR 9802441 A TR9802441 A TR 9802441A TR 199802441 A3 TR199802441 A3 TR 199802441A3
Authority
TR
Turkey
Prior art keywords
prevention
blood
treatment
composition
uric acid
Prior art date
Application number
TR1998/02441A
Other languages
English (en)
Other versions
TR199802441A2 (tr
Inventor
Fujiwara Toshihiko
Iwasaki Koichi
Horikoshi Hiroyoshi
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of TR199802441A3 publication Critical patent/TR199802441A3/tr
Publication of TR199802441A2 publication Critical patent/TR199802441A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
TR1998/02441A 1997-11-25 1998-11-25 Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip. TR199802441A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32318297 1997-11-25

Publications (2)

Publication Number Publication Date
TR199802441A3 true TR199802441A3 (tr) 1999-10-21
TR199802441A2 TR199802441A2 (tr) 1999-10-21

Family

ID=18151987

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02441A TR199802441A2 (tr) 1997-11-25 1998-11-25 Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.

Country Status (23)

Country Link
US (1) US6353009B1 (tr)
EP (1) EP0919232B1 (tr)
KR (1) KR19990045531A (tr)
AR (1) AR011231A1 (tr)
AT (1) ATE278400T1 (tr)
AU (1) AU744653B2 (tr)
BR (1) BR9805012A (tr)
CA (1) CA2254394C (tr)
CZ (1) CZ378898A3 (tr)
DE (2) DE69826811T4 (tr)
ES (1) ES2230657T3 (tr)
HK (1) HK1020259A1 (tr)
HU (2) HUP9902721A2 (tr)
ID (1) ID21332A (tr)
IL (1) IL127219A (tr)
NO (1) NO985484L (tr)
NZ (1) NZ332895A (tr)
PL (1) PL329893A1 (tr)
RU (1) RU2190425C2 (tr)
SA (1) SA99191266A (tr)
TR (1) TR199802441A2 (tr)
TW (1) TW592697B (tr)
ZA (1) ZA9810788B (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
AU3195700A (en) * 1999-05-27 2000-12-18 Tanabe Seiyaku Co., Ltd. Remedies for kidney diseases and method for screening the same
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6784199B2 (en) 2000-09-21 2004-08-31 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CA2476594C (en) * 2002-03-05 2012-10-09 Transtech Pharma, Inc. Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
AU2004251599A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
JP2005092923A (ja) * 2003-09-12 2005-04-07 Renesas Technology Corp 半導体記憶装置
JP2008506785A (ja) * 2004-07-21 2008-03-06 フロリダ大学 リサーチファウンデーション インコーポレイティッド インスリン抵抗性の治療及び予防のための組成物及び方法
EP1919472B1 (en) * 2005-07-21 2021-09-01 University of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
NZ580588A (en) * 2007-04-05 2011-12-22 Daiichi Sankyo Co Ltd Fused bicyclic heteroaryl derivatives
JPWO2010101164A1 (ja) 2009-03-05 2012-09-10 第一三共株式会社 ピリジン誘導体
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
CA2862602A1 (en) * 2012-01-27 2013-08-01 Teijin Pharma Limited Therapeutic agent for diabetes
WO2014190138A2 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
US20190152967A1 (en) * 2016-04-04 2019-05-23 The Schepens Eye Research Institute, Inc. Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4703052A (en) * 1985-05-21 1987-10-27 Pfizer Inc. Hypoglycemic thiazolidinediones
ZA873745B (en) 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
EP0306228B1 (en) 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US4897405A (en) 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469383A (ja) 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
CA2137778A1 (en) * 1992-07-02 1994-01-20 Birgitte Yde Polymerization of lignin at alkaline ph
GB9223059D0 (en) 1992-11-04 1992-12-16 Bamford Excavators Ltd Intercooler apparatus
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JPH06211657A (ja) 1993-01-21 1994-08-02 Mochida Pharmaceut Co Ltd 尿酸排泄剤
CN1103590C (zh) 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
WO1995018125A1 (fr) * 1993-12-27 1995-07-06 Japan Tobacco Inc. Derive d'isoxazolidinedione et son utilisation
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
CA2159938A1 (en) 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Also Published As

Publication number Publication date
CZ378898A3 (cs) 1999-07-14
US6353009B1 (en) 2002-03-05
ID21332A (id) 1999-05-27
RU2190425C2 (ru) 2002-10-10
DE69826811T4 (de) 2006-09-21
ES2230657T3 (es) 2005-05-01
ZA9810788B (en) 1999-05-25
NO985484L (no) 1999-05-26
AR011231A1 (es) 2000-08-02
BR9805012A (pt) 2000-03-21
KR19990045531A (ko) 1999-06-25
IL127219A (en) 2001-08-08
TW592697B (en) 2004-06-21
HUP9902721A2 (hu) 1999-12-28
CA2254394C (en) 2009-11-17
EP0919232A1 (en) 1999-06-02
IL127219A0 (en) 1999-09-22
HK1020259A1 (en) 2000-04-07
EP0919232B1 (en) 2004-10-06
HUP9802721A1 (hu) 2000-03-28
CA2254394A1 (en) 1999-05-25
DE69826811T2 (de) 2005-06-16
SA99191266A (ar) 2005-12-03
AU744653B2 (en) 2002-02-28
PL329893A1 (en) 1999-06-07
ATE278400T1 (de) 2004-10-15
TR199802441A2 (tr) 1999-10-21
AU9410298A (en) 1999-06-17
HU9802721D0 (en) 1999-01-28
NZ332895A (en) 2001-04-27
DE69826811D1 (de) 2004-11-11
NO985484D0 (no) 1998-11-24

Similar Documents

Publication Publication Date Title
TR199802441A3 (tr) Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.
MXPA01009415A (es) COMPOSICION DE ACIDO ASCORBICO Y METODO PARA TRATAMIENTO DE PIEL DAnADA O ENVEJECIDA.
DE69711034T2 (de) Wässrige fluorpolymerlösungen zur behandlung von harten oberflächen
DE69621830T2 (de) Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase-inhibitoren
HK1048949A1 (en) Method and composition for the treatment of scars
ATE298241T1 (de) Behandlung von atemstillstand im schlaf
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
ZA991489B (en) Oxaliplatin solution formulations and the method of use thereof.
ID21863A (id) Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak
DE60001735D1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
DE69714862D1 (de) Lösungen und verfahren zur oberblächenbehandlung von metallen
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
DE69828985D1 (de) Lichtgebender katheter sowie anwendungsverfahren
NO972426D0 (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE69717846D1 (de) Behandlungsverfahren von laktamen
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DK0915655T3 (da) Fremgangsmåde og sammensætning til behandling mod parasitter i dyrs omgivelser
AU3996799A (en) Alpha amino acid composition and method for the treatment of skin
NO20022990L (no) Fremgangsmåte og sammensetning for behandling av smerte
ATA93695A (de) Mittel zur behandlung von strahlenschäden
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose